| | Other Issues: previous | next | latest | archiveLetters Luminal B breast tumors are not HER2 positive Rohit Bhargava and David J Dabbs PMCID: PMC2614503 Luminal B breast tumors are not HER2 positive – authors' response Rulla M Tamimi, Stuart J Schnitt, Graham A Colditz, and Laura C Collins PMCID: PMC2614507 Viewpoint Highway to heaven: mammary gland development and differentiation Lorenzo Melchor and Matthew J Smalley PMCID: PMC2614513 Research Articles A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study Flavia Novelli, Michele Milella, Elisa Melucci, Anna Di Benedetto, Isabella Sperduti, Raffaele Perrone-Donnorso, Letizia Perracchio, Irene Venturo, Cecilia Nisticò, Alessandra Fabi, Simonetta Buglioni, Pier Giorgio Natali, and Marcella Mottolese PMCID: PMC2614505 The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas Jason I Herschkowitz, Xiaping He, Cheng Fan, and Charles M Perou PMCID: PMC2614508 ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients Tanja Fehm, Natalia Krawczyk, Erich-Franz Solomayer, Graziella Becker-Pergola, Silke Dürr-Störzer, Hans Neubauer, Harald Seeger, Annette Staebler, Diethelm Wallwiener, and Sven Becker PMCID: PMC2614509 Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials Sibylle Loibl, Gunter von Minckwitz, Nadia Harbeck, Wolfgang Janni, Dirk Elling, Manfred Kaufmann, Holm Eggemann, Valentina Nekljudova, Harald Sommer, Marion Kiechle, and Sherko Kümmel PMCID: PMC2614510 Menopausal hormone therapy in relation to breast cancer characteristics and prognosis: a cohort study Lena U Rosenberg, Fredrik Granath, Paul W Dickman, Kristjana Einarsdóttir, Sara Wedrén, Ingemar Persson, and Per Hall PMCID: PMC2614511 Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer Signe Borgquist, Annika Jögi, Fredrik Pontén, Lisa Rydén, Donal J Brennan, and Karin Jirström PMCID: PMC2614512 Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients Galatea Kallergi, Sofia Agelaki, Antonia Kalykaki, Christos Stournaras, Dimitris Mavroudis, and Vassilis Georgoulias PMCID: PMC2614515 Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer Katja Lundgren, Karolina Holm, Bo Nordenskjöld, Åke Borg, and Göran Landberg PMCID: PMC2614516 Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours Jürgen Veeck, Nuran Bektas, Arndt Hartmann, Glen Kristiansen, Uwe Heindrichs, Ruth Knüchel, and Edgar Dahl PMCID: PMC2614517 Recurrence dynamics does not depend on the recurrence site Romano Demicheli, Elia Biganzoli, Patrizia Boracchi, Marco Greco, and Michael W Retsky PMCID: PMC2614518 Targeting aspartate aminotransferase in breast cancer Joshua Marshall Thornburg, Kristin K Nelson, Brian F Clem, Andrew N Lane, Sengodagounder Arumugam, Allan Simmons, John W Eaton, Sucheta Telang, and Jason Chesney PMCID: PMC2614520 Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1 Hans Neubauer, Susan E Clare, Wojciech Wozny, Gerhard P Schwall, Slobodan Poznanović, Werner Stegmann, Ulrich Vogel, Karl Sotlar, Diethelm Wallwiener, Raffael Kurek, Tanja Fehm, and Michael A Cahill PMCID: PMC2614521 Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes Golareh Habibi, Samuel Leung, Jennifer H Law, Karen Gelmon, Hamid Masoudi, Dmitry Turbin, Michael Pollak, Torsten O Nielsen, David Huntsman, and Sandra E Dunn PMCID: PMC2614522 Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma Nadia P Castro, Cynthia ABT Osório, César Torres, Elen P Bastos, Mário Mourão-Neto, Fernando A Soares, Helena P Brentani, and Dirce M Carraro PMCID: PMC2614523 A candidate molecular signature associated with tamoxifen failure in primary breast cancer Julie A Vendrell, Katherine E Robertson, Patrice Ravel, Susan E Bray, Agathe Bajard, Colin A Purdie, Catherine Nguyen, Sirwan M Hadad, Ivan Bieche, Sylvie Chabaud, Thomas Bachelot, Alastair M Thompson, and Pascale A Cohen PMCID: PMC2614524 Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer Elton Rexhepaj, Donal J Brennan, Peter Holloway, Elaine W Kay, Amanda H McCann, Goran Landberg, Michael J Duffy, Karin Jirstrom, and William M Gallagher PMCID: PMC2614526 Selective segregation of DNA strands persists in long label retaining mammary cells during pregnancy Brian W Booth, Corinne A Boulanger, and Gilbert H Smith PMCID: PMC2614527 Serial analysis of gene expression of lobular carcinoma in situ identifies down regulation of claudin 4 and overexpression of matrix metalloproteinase 9 Dengfeng Cao, Kornelia Polyak, Marc K Halushka, Hind Nassar, Nina Kouprina, Christine Iacobuzio-Donahue, Xinyan Wu, Saraswati Sukumar, Jessica Hicks, Angelo De Marzo, and Pedram Argani PMCID: PMC2614499 Prospective study of physical activity and risk of postmenopausal breast cancer Michael F Leitzmann, Steven C Moore, Tricia M Peters, James V Lacey, Jr, Arthur Schatzkin, Catherine Schairer, Louise A Brinton, and Demetrius Albanes PMCID: PMC2614500 Reviews Unlocking the power of cross-species genomic analyses: identification of evolutionarily conserved breast cancer networks and validation of preclinical models Christina N Bennett and Jeffrey E Green PMCID: PMC2614501 Functional genomic analysis of drug sensitivity pathways to guide adjuvant strategies in breast cancer Charles Swanton, Zoltan Szallasi, James D Brenton, and Julian Downward PMCID: PMC2614525 Editorials A gene signature of loss of oestrogen receptor (ER) function and oxidative stress links ER-positive breast tumours with an absent progesterone receptor and a poor prognosis Patrick Neven, Toon Van Gorp, and Karen Deraedt PMCID: PMC2614504 Breast cancer stem cell markers – the rocky road to clinical applications Gabriela Dontu PMCID: PMC2614502 The evolving role of oestrogen receptor beta in clinical breast cancer Valerie Speirs PMCID: PMC2614506 On the way to specifically targeting minimal residual disease? Gerhard Gebauer PMCID: PMC2614514 Correction Correction: BCoR-L1 variation and breast cancer Felicity Lose, Jeremy Arnold, David B Young, Carolyn J Brown, Graham J Mann, Gulietta M Pupo, The Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Kum Kum Khanna, Georgia Chenevix-Trench, and Amanda B Spurdle PMCID: PMC2614519 Corrects:Felicity Lose, et al. BCoR-L1 variation and breast cancer. Breast Cancer Res. 2007; 9(4): R54. |
